DNTH
Dianthus Therapeutics, Inc.
Stock
$88.21−0.11 (−0.12%)Close Oct 2, 2026
Cash flow statement
| Line | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | −$155M | −$129M | −$78M | −$37M | −$29M | −$60M | −$64M | −$57M | −$42M | −$22M | −$6.5M |
| Capital expenditures | $334K | $213K | $105K | $110K | $314K | $1.3M | $400K | $3.1M | $7.7M | $2.2M | $139K |
| Free cash flow | −$156M | −$129M | −$78M | −$37M | −$29M | −$61M | −$64M | −$60M | −$50M | −$24M | −$6.7M |
| Stock-based compensation | $34M | $23M | $13M | $2.9M | $1.5M | $10M | $9.9M | $10M | $11M | $2.3M | $662K |
| Dividends per share | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — | — | — | — |
| Free cash flow margin | — | −6,349.4% | −1,255.6% | −1,308.2% | — | — | — | — | — | — | — |